2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
7
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uterine Cervical Neoplasms
2
Polycystic Ovary Syndrome
2
Vaginal Atrophy
1
Triple Negative Breast Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Metastatic Breastcancer
1
Insulin Resistance
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Depression
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms, Male
1
Atrophic Vaginitis
1
Anxiety Disorders
1
Anus Neoplasms
1
Interventions
Gemcitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
parathyroid hormone-related peptide (1-36)
2
niraparib
2
Ocoxin
2
Musculoskeletal Manipulations
2
Metformin
2
Clomiphene
2
Cisplatin
2
repotrectinib
1
relacorilant
1
pralsetinib
1
pembrolizumab
1
napabucasin
1
lutetium Lu 177 dotatate
1
fluorodopa F 18
1
copper dotatate CU-64
1
anlotinib
1
adrenosterone
1
Ultrasonography
1
Thalidomide
1
Sunitinib
1
Spironolactone
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endocrine System Diseases
×
Dehydroepiandrosterone
×
Clear all
NCT05263557
2023-07-25
DIMOXIS
Royal College of Surgeons, Ireland
Phase NA
Unknown
20 enrolled